Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$166.15 USD
-0.92 (-0.55%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $166.16 +0.01 (0.01%) 7:10 PM ET
4-Sell of 5 4
C Value F Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
JNJ 166.15 -0.92(-0.55%)
Will JNJ be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for JNJ based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for JNJ
ISRG Stock Rallies 14% in 3 Months: Is It Still Worth Buying?
Johnson & Johnson (JNJ) Exceeds Market Returns: Some Facts to Consider
JNJ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
TEVA Stock Rises 72.5% This Year: Time to Buy, Sell or Hold?
Pharma Stock Roundup: FDA Approves J&J's Tremfya for Ulcerative Colitis & More
Other News for JNJ
JNJ December 20th Options Begin Trading
BlackRock Advantage Global Fund Q2 2024 Commentary
Citi Keeps Their Buy Rating on Johnson & Johnson (JNJ)
BeiGene initiated at outperform at JMP Securities on strength of Brukinsa
Chinese Biotech BeiGene Labeled 'Unique Investment' As Analyst Confident In Lead Cancer Drug